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SHORT COMMUNICATION
Anthracycline-induced toxicity affecting palmar and plantar skin
A.P. Jones' & S.M. Crawford2
1Department of Medical Oncology, Bradford Royal Infirmary, Bradford BD9 6RJ, UK and 2Director of the Clinical
Oncology Unit, Bradford University, Bradford BD7 JDP, UK.
We wish to report an adverse effect of frequent adminis-
tration of anthracycline cytotoxic drugs, affecting both nails
and the palmar and plantar skin.
Case 1
J.K., a 70-year-old woman, presented with liver metastases
from a carcinoma of uncertain origin. She received chemo-
therapy including doxorubicin (Adriamycin) at a dose of
20mg per square metre per week (36mg weekly), as a bolus.
After 5 weeks she developed painful erythema of the palms
and soles, which was followed by desquamation at these
sites. On withdrawal of the doxorubicin the skin of both
areas returned to normal over the next 2 weeks.
Case 2
V.C., a 66-year-old woman received epirubicin (Pharmorubi-
cin) as a bolus dose of 40mg per square metre per week, for
granulosa cell carcinoma of the ovary. After 3 weeks she
developed painful desquamation of the plantar skin, with
loosening and opacity of both the finger and toe nails. On
withdrawal of epirubicin the skin changes returned to
normal over the course of one month.
Case 3
M.W., a 69-year-old lady received a fortnightly bolus of
doxorubicin for a metastatic breast carcinoma. She subse-
quently developed a painful plantar erythema, with desquam-
ation and onycholysis of toe nails. On stopping treatment
her feet returned to normal over a period of one month.
Similar changes have previously been noted in patients on
continuous low dose infusions of chemotherapeutic agents,
notably 5-fluorouracil and doxorubicin (Lokich, 1984;
Vogelzang, 1985). Onycholysis was recently reported as a
consequence of chemotherapy, including anthracyclines in
three patients (Cunningham et al., 1985). All three, however,
had biochemical evidence of zinc deficiency which may have
been a contributory factor. Mitozantrone has also been
implicated as causing onycholysis in two patients on single
agent therapy for carcinoma of the breast (Speechley-Dick et
al., 1988). In none of these cases was the palmar or plantar
skin involved.
We report skin changes involving the hands and feet, with
or without onycholysis, in patients receiving frequent low-
dose intermittent anthracycline therapy. While this is clearly
not a life-threatening toxic effect, it may still be the cause of
sufficient discomfort to require withdrawal of these agents.
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